Records containing: Hepatitis C Virus

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2015-10-23
  A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
• CLINICAL_TRIALS study record update · 2015-10-20
  ClinicalTrials.gov study NCT02058173
• CLINICAL_TRIALS study record update · 2015-10-12
  A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy
• CLINICAL_TRIALS study record update · 2015-10-09
  A Phase 3, Open-Label Study With Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin With Chronic Hepatitis C Genotypes 1 or 4 Infection
• CLINICAL_TRIALS study record update · 2015-10-09
  A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2015-10-09
  A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
• CLINICAL_TRIALS study record update · 2015-10-09
  A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotypes 1 and 4 Chronic Hepatitis C Infection
• CLINICAL_TRIALS study record update · 2015-09-23
  A Pilot Study of the Grapefruit Flavonoid Naringenin for the Treatment of HCV Infection
• CLINICAL_TRIALS study record update · 2015-06-25
  Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C
• CLINICAL_TRIALS study record update · 2015-05-22
  A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection.
• CLINICAL_TRIALS study record update · 2015-01-09
  An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects
• CLINICAL_TRIALS study record update · 2015-01-08
  An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
• CLINICAL_TRIALS study record update · 2014-12-10
  ClinicalTrials.gov study NCT00819026
• CLINICAL_TRIALS study record update · 2014-11-25
  A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection
• CLINICAL_TRIALS study record update · 2014-05-09
  Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C
• CLINICAL_TRIALS study record update · 2014-02-19
  A Multi-center, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1, and an Open Label Assessment of PSI-7977 in Patients With HCV Genotypes 2 or 3
• CLINICAL_TRIALS study record update · 2014-01-14
  A Phase 1, Non- Randomized, Open Label, Sequential Group, Multicenter Study To Evaluate The Antiviral Activity Of Multiple Doses Of A Small Molecule Direct Antiviral Agent In Chronically Infected Hepatitis C Subjects.
• CLINICAL_TRIALS study record update · 2013-11-13
  High Dose Insulin Therapy to Improve Liver Function in Patients With HCV Liver Cirrhosis
• CLINICAL_TRIALS study record update · 2013-10-14
  A Phase I, Open-label, Sequential Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of TMC435 in Subjects With Moderately or Severely Impaired Hepatic Function
• CLINICAL_TRIALS study record update · 2013-10-14
  Phase I, Open-label Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435
• CLINICAL_TRIALS study record update · 2013-08-09
  Hepatitis C Virus and the Humoral Immune System
• CLINICAL_TRIALS study record update · 2013-07-18
  A Randomized, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-791325 in Healthy Japanese Subjects
• CLINICAL_TRIALS study record update · 2013-07-01
  A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C
• CLINICAL_TRIALS study record update · 2013-05-17
  Pilot Study to Assess Gut Mucosal B Cells in Individuals Co-Infected With HCV and HIV
• CLINICAL_TRIALS study record update · 2013-05-06
  Photosensitivity Trial. A Randomized, Double-blind, Double Dummy, Placebo- and Positive Controlled Phase I Trial to Evaluate the Photosensitizing Potential of TMC435 in Healthy Subjects.